Calza N., Manfredi R., Colangeli V., Chiodo F.Systemic lupus erythematosus and HIV infection. A case report and review of literature. Recent Prog Med2002; 93: 28-31.
2.
Palacios R., Santos J., Valdivielso P., Marquez M.Human immunodeficiency infection and systemic lupus erythematosus. An unusual case and a review of the literature. Lupus2002 ; 11: 60-63.
3.
Molina JF, Citera G., Rosler D., et al. Coexistence of human immunodeficiency virus infection and systemic lupus erythematosus. J Rheumatol1995; 22: 347-350.
4.
D’Agati V., Appel GBRenal pathology of human immunodeficiency virus. Semin Nephrol1998; 18: 406-421.
5.
Neboloni M., Barbiano di Belgiojoso G., Genderini A., et al. Glomerular lesions in HIV positive patients: a 20-year biopsy experience from Northern Italy. Clin Nephrol2009; 72: 38-45.
6.
Mak A., Cheak AA, Tan JY, Su HC, Ho RC, Lau CSMycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression . Rheumatology (Oxford) 2009; 48: 944-952.
7.
Jones RB, Walsh M., Smith KGWhat is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?Curr Opin Rheumatol2009 ; 21: 256-261.
8.
Chapuis A., Rizzardi P., D’Agostino C., et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nature Med2000; 6: 762-768.
9.
García F., Plana M., Arnedo M., et al. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. J Acquir Immune Defic Syndr2004; 1: 823-830.
